港股異動 | 香港醫思醫療三日連升累漲近20% 料年度銷售額不少於去年同期
格隆匯4月6日丨香港醫思醫療集團(2138.HK)現報3.98港元,漲6.7%,暫成交408萬港元,最新總市值39億港元。公司上週四(2日)早間公佈,預期截至2020年3月31日止的年度的銷售額(為集團訂約銷售及提供的所有產品及服務產生的銷售額)將不少於去年同期。董事會認為,雖然自2019年8月和2020年2月以來整體業務分別受到香港社會不穩定和Covid-19疫情的影響,集團保持穩健且其數碼化戰略仍然促進了業務互動及交流。公告發布後至今,該股已連續三個交易日上漲,現較4月1日的收盤價3.33港元已累漲近20%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.